Targeting novel regulated cell death: Ferroptosis, pyroptosis and necroptosis in anti‐PD ‐1/ PD‐L1 cancer immunotherapy
Cell Proliferation · 2024-08 · 57 (8)
DOI: 10.1111/cpr.13644 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell Proliferation, online erschienen am 09.04.2024. Verfasst von Li Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Health Science Center, Yangtze University, Jingzhou, Hubei, China. Hauptthemen laut MEDLINE: Pyroptosis, Ferroptosis, Neoplasms, Necroptosis. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Belt and Road Initiative Innovative Talent Exchange Foreign Expert Project, Singapore Ministry of Health's National Medical Research Council, Joint NCIS and NUS Cancer Pro-gram Seed Funding Grants.
Abstract (Originalsprache)
Chemotherapy, radiotherapy, and immunotherapy represent key tumour treatment strategies. Notably, immune checkpoint inhibitors (ICIs), particularly anti‐programmed cell death 1 (PD1) and anti‐programmed cell death ligand 1 (PD‐L1), have shown clinical efficacy in clinical tumour immunotherapy. However, the limited effectiveness of ICIs is evident due to many cancers exhibiting poor responses to this treatment. An emerging avenue involves triggering non‐apoptotic regulated cell death (RCD), a significant mechanism driving cancer cell death in diverse cancer treatments. Recent research demonstrates that combining RCD inducers with ICIs significantly enhances their antitumor efficacy across various cancer types. The use of anti‐PD‐1/PD‐L1 immunotherapy activates CD8 + T cells, prompting the initiation of novel RCD forms, such as ferroptosis, pyroptosis, and necroptosis. However, the functions and mechanisms of non‐apoptotic RCD in anti‐PD1/PD‐L1 therapy remain insufficiently explored. This review summarises the emerging roles of ferroptosis, pyroptosis, and necroptosis in anti‐PD1/PD‐L1 immunotherapy. It emphasises the synergy between nanomaterials and PD‐1/PD‐L1 inhibitors to induce non‐apoptotic RCD in different cancer types. Furthermore, targeting cell death signalling pathways in combination with anti‐PD1/PD‐L1 therapies holds promise as a prospective immunotherapy strategy for tumour treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Health Science Center, Yangtze University, Jingzhou, Hubei, China.
- Department of Urology, Jingzhou Central Hospital, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, Hubei, China.
- Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
- NUS Centre for Cancer Research (N2CR), National University of Singapore, Singapore, Singapore.
ORCID-Profile: Li Yu, Gautam Sethi, Zhaowu Ma
Förderung
- Belt and Road Initiative Innovative Talent Exchange Foreign Expert Project
- Singapore Ministry of Health's National Medical Research Council
- Joint NCIS and NUS Cancer Pro-gram Seed Funding Grants
Zitieren
APA
Yu, L., Huang, K., Liao, Y., Wang, L., Sethi, G., & Ma, Z. (2024). Targeting novel regulated cell death: Ferroptosis, pyroptosis and necroptosis in anti‐PD ‐1/ PD‐L1 cancer immunotherapy. Cell Proliferation, 57(8). https://doi.org/10.1111/cpr.13644
Vancouver
Yu L, Huang K, Liao Y, Wang L, Sethi G, Ma Z. Targeting novel regulated cell death: Ferroptosis, pyroptosis and necroptosis in anti‐PD ‐1/ PD‐L1 cancer immunotherapy. Cell Proliferation. 2024;57(8). doi:10.1111/cpr.13644
BibTeX
@article{Yu2024,
author = {Yu, Li and Huang, Ke and Liao, Yixiang and Wang, Lingzhi and Sethi, Gautam and Ma, Zhaowu},
title = {Targeting novel regulated cell death: Ferroptosis, pyroptosis and necroptosis in anti‐PD ‐1/ PD‐L1 cancer immunotherapy},
journal = {Cell Proliferation},
year = {2024},
volume = {57},
number = {8},
doi = {10.1111/cpr.13644}
}
EUVIMED